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Circulating microRNAs are potential biomarkers of type 2 diabetes mellitus (T2DM) and
related complications. Here, we investigated the association of microRNA-15a with early
retinal damage in T2DM. A cohort of untreated subjects screened for intermediate/high
risk of T2DM, according to a score assessment questionnaire, and then recognized to
have a normal (NGT) or impaired (IGT) glucose tolerance or T2DM was studied. The
thickness of the ganglion cell complex (GCC), an early marker of retinal degeneration
anteceding overt retinopathy was assessed by Optical Coherence Tomography. Total and
extracellular vesicles (EV)-associated microRNA-15a quantity was measured in plasma
by real time PCR. MicroRNA-15a level was significantly higher in subjects with IGT and
T2DM compared with NGT. MicroRNA-15a abundance was correlated to body mass
index and classical diabetes biomarkers, including fasting glucose, HbA1c, insulinemia,
and HOMA-IR. Moreover, GCC thickness was significantly reduced in IGT and T2DM
subjects compared with NGT controls. Importantly, total microRNA-15a correlated with
GCC in IGT subjects, while in T2DM subjects, EV-microRNA-15a negatively correlated
with GCC, suggesting that microRNA-15a may monitor initial retinal damage. The
assessment of plasma microRNA-15a may help refining risk assessment and secondary
prevention in patients with preclinical T2DM.
Keywords: prediction and prevention of type 2 diabetes, retinopathy, microvascular disease, microRNA-15a,
extracellular vesicles
INTRODUCTION
The number of adults affected by type 2 diabetes mellitus (T2DM) and the proportion of
T2DM patients with vascular and neurological complications is expected to grow substantially
in future decades (1). Therefore, prognostic biomarkers capable of establishing clinical practice
recommendations for patients who have impaired glucose tolerance (IGT) and are at increased
risk of developing T2DM-releated complications are urgently needed (2). High levels of plasma
glucose are associated with increased insulin production by the pancreatic beta cells and insulin
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resistance in peripheral tissues, resulting in endothelial
dysfunction, microvascular damage, and neural degeneration.
In the context of retinopathy, the neurodegenerative theory
hypothesizes early anatomical changes occur in the ganglionic
cell complex (GCC), prior to the onset of microangiopathy.
GCC can be assessed by the specialist using Optical Coherence
Tomography (OCT), a test that uses light waves to take cross-
sectional pictures of the retina. On the other hand, there is a
need to identify reliable biomarkers from an easily accessible
source that could generate cost-effective assays feasible for
routine screening. Blood-based biomarkers may offer a non-
invasive strategy to improve risk assessment in individuals
with preclinical or uncomplicated T2DM (3). We and others
reported that specific circulating microRNA signatures may
help predicting or detecting the development and progression
of T2DM at an early stage (4, 5). MicroRNAs are small (20–22
bp) non-coding RNA molecules that act as post-transcriptional
regulators of gene expression in the cell of origin as well as in
neighbor and distant cells. After secretion and transport through
the circulation, microRNAs are shuttled to target cells by proteins
(e.g., Ago-2 and high density lipoproteins) and extracellular
vesicles (EVs) (6, 7). High levels of microRNA-15a associate
with an increased risk of post-revascularization amputation in
T2DM subjects with severe peripheral vascular complications
(8). Moreover, a recent study demonstrated that high levels
of extracellular vesicles (EV)-associated microRNA-15a can
be found in plasma of subjects with diabetic retinopathy (9).
Here, we report a pilot observational study aimed to provide
TABLE 1 | Anamnestic and laboratory tests data characterizing the study population.
NGT (N = 26) IGT (N = 24) T2DM (N = 26)
n (%) n (%) n (%) p**
mean SD mean SD mean SD
SEX (males) 9 (34.6) 12 (50.0) 10 (38.5) 0.5◦
Age (years) 56 9.6 62.5 8.3 61.2 7.8 0.02*
FPG (mg/dL) 82.1 8 94.5 10 110.2 14.7 <0.0001
OGTT (mg/dL) 99.8 22.9 157.8 16.1 238.3 39.9 <0.0001
HbA1c (%) 5.6 0.3 6.2 0.4 6.6 0.6 <0.0001*
HbA1c (mmol/mol) 38.1 2.8 43.7 4 48.9 6.4 0.01
Insulin (mlU/L) 16.6 22.4 19.6 30.5 20.5 20.4 0.0005
HOMA-IR 3.4 4.6 4.7 7.5 5.7 6 0.02
SBP (mmHg) 128.5 12.3 132.7 20.2 132.5 15.1 0.4*
DBP (mmHg) 73.1 11.8 79 11 80.1 13 0.5
Heart rate (bpm) 69.8 8.8 68.8 7.8 73 7.2 0.01
BMI (Kg/m2) 25.2 3.7 26.6 3.6 29 5.7 0.09
Waist circumference (cm) 92.4 11.8 98.3 8.5 100.1 12.2 0.5
Total cholesterol (mg/dL) 201.5 32.8 215.2 34.5 202.3 31.6 0.2
HDL cholesterol (mg/dL) 57.3 12.4 53.6 13.5 52.1 13.1 0.3*
LDL cholesterol (mg/dL) 122.3 28.4 136.2 33.1 124.6 27.1 0.3*
Triglycerides (mg/dL) 109.6 63.5 127.2 54.8 128.3 63.5 0.2*
Microalbuminuria (mg/dL) 6.5 5.2 29.2 83 18.3 32.1 0.2
Oral glucose tolerance test (OGTT) refers to plasma glucose level measured 2 h post 75 gr of glucose load. FPG, fasting plasma glucose; BMI, body mass index; SBP, sistolic blood
pressure; DBP, diastolic blood pressure.The reported p-values refer to ◦ chi-squared test *F test **Kruskal-Wallis test. Significant p-values are in bold.
initial evidence for the usefulness of total and EV-microRNA-
15a as an early biomarker of complications in patients with
preclinical T2DM.
RESULTS
Clinical and Laboratory Characteristics
Characteristics of the 76 enrolled subjects are shown in (Table 1).
Subjects in the IGT and T2DM groups tended to be older
compared with control therefore age was always taken into
consideration for subsequent analyses. The analysis of GCC was
performed in a subgroup of patients who gave consent or were
eligible for an OCT test, according to the criteria described in the
Methods section. In total, we analyzed 33 eyes of NGT subjects,
31 of IGT, and 30 of T2DM. Results indicate the average GCC
thickness was significantly decreased in subjects with IGT or
T2DM as compared with NGT (Figures 1A,B).
High Abundance of Circulating
microRNA-15a in Subjects With
Newly-Diagnosed T2DM
By quantitative RT-PCR, we measured the levels of microRNA-
15a (normalized by an exogenous spike-in RNA, Cel-microRNA-
39) in the plasma of subjects with newly-diagnosed T2DM
(n= 26), IGT (n = 24), or NGT (n = 26). Circulating levels
of total plasma microRNA-15a were significantly different in
the three groups (overall p = 0.001), after adjustment by age
and sex. Moreover, a significant difference was observed in the
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FIGURE 1 | Thickness of the ganglionic cell complex (GCC) decrease in
subject with IGT and T2D. (A) Box plot of GCC thickness (µm) in the three
diagnostic groups. Overall p = 0.02. T2DM vs. NGT p = 0.048. IGT vs. NGT p
= 0.04. Boxes are bordered at the 25th and the 75th percentile of the
predictor variable and a median line at the 50th percentile. Whiskers extend
from the box to the upper and lower adjacent values and are capped with an
adjacent line. Points below and above the whiskers (10–90th percentile) are
drawn as individual dots. (B) Representative images and color grade (white
indicating normal and red most reduced GCC thickness).
comparison of T2DM with NGT (p < 0.0001) (Figure 2A).
In addition, we found a significant association between the
microRNA-15a and markers of altered glucose metabolism,
including HbA1c, plasma glucose, insulin, and HOMA-IR
(Table 2, left).
To determine the value of microRNA-15a as a biomarker for
diagnosis of IGT orT2DM, the receiving operator characteristic
(ROC) curves were drawn and the area under the curve (AUC)
calculated (Figure 2B). Results demonstrate the diagnostic
accuracy of microRNA-15a for T2DM (AUC = 0.83, 95% CI
0.71–0.94) and IGT (AUC = 0.66, 95% CI 0.51–0.82). In both
cases, microRNA-15a has a limitative discriminative power with
respect to HbA1c (p-value for comparison between ROC curves
0.008 and 0.029, respectively).
The Abundance of EV-microRNA-15a
Negatively Correlates With GCC Thickness
in T2D Subjects
To explore if EVs-contained microRNA-15a has a different
diagnostic value compared to its whole circulating plasma level,






N rho* p N rho* p
Age (years) 76 0.04 0.7 55 0.04 0.7
FPG (mg/dL) 76 0.3 0.01 55 0.3 0.03
OGTT (mg/dL) 76 0.4 <0.0001 55 0.4 0.002
HbA1c (%) 76 0.3** 0.02 55 0.4 0.01
HbA1c (mmol/mol) 76 0.4 0.002 55 0.4 0.01
Insulin (mlU/L) 73 0.3 0.01 55 0.4 0.002
HOMA-IR 73 0.3 0.003 55 0.4 0.002
SBP (mmHg) 76 0.3 0.01 55 0.3 0.05
DBP (mmHg) 76 0.3 0.002 55 0.3 0.048
Heart rate (bpm) 76 0.1 0.3 55 0.03 0.8
BMI (Kg/m2) 76 0.2** 0.045 55 0.3 0.04
Waist circumference (cm) 76 0.2** 0.046 55 0.3 0.06
Total cholesterol (mg/dL) 76 −0.01** 0.9 55 0.04 0.8
HDL cholesterol (mg/dL) 76 −0.2 0.1 55 −0.1 0.4
LDL cholesterol (mg/dL) 76 −0.01** 0.9 55 0.04 0.8
Triglycerides (mg/dL) 76 0.2 0.1 55 0.2 0.1
Microalbuminuria (mg/dL) 74 0.1 0.4 55 −0.07 0.6
Oral glucose tolerance test (OGTT) refers to plasma glucose level measured 2 h post 75
gr of glucose load. FPG, fasting plasma glucose. DBP, diastolic blood pressure. SBP,
sistolic blood pressure. The reported p-values refer to *Spearman’s correlation with miR
expression **Pearson’s correlation coefficient with miR expression. Significant p-values
are in bold.
we isolated circulating EVs with size-exclusion chromatography.
We found that NGT subjects were characterized by a higher
concentration of smaller vesicles, with a peak at 93 nm. When
comparing IGT and T2DM subjects, the size distribution
was similar, but the small size EV component was present
only in the IGT group (Figure 3A). Next, we assessed the
level of microRNA-15a contained in EVs. Results indicate the
quantity of EV-microRNA-15a is different between the three
diagnostic groups (overall p < 0.05). Particularly, T2DM subjects
presented significantly higher values if compared with NGT
subjects (p = 0.003) (Figure 3B). Of note, T2DM subjects
also showed a significant increase in EV-miRNA-15a quantity
embedded in small size EV (30–100 nM in size) (p = 0.02 vs.
NGT) (Figure 3C). Moreover, similarly to what we observed
for total circulating microRNA-15a, EV-microRNA-15a levels
associate with clinical parameter of altered glucose metabolism
(Table 2, right).
Finally, we analyzed the correlation between total plasma-
microRNA-15a or EV-microRNA-15a and GCC (Figure 4).
Adjusting by age and sex no association was found between total
plasma microRNA-15a and GCC in T2DM, but a significant
correlation was observed in IGT (p = 0.0094 rho = 0.474).
Moreover, results indicate a significant positive correlation of
EV-microRNA-15 quantity and GCC thickness in NGT (p =
<0.0001, rho = 0.677), but not in T2D (p = 0.062, rho = −0.37)
and IGT (p = 0.87, rho = 0.034) subjects. Similarly, the fraction
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FIGURE 2 | IGT and T2DM subjects bear high levels of circulating microRNA-15a. (A) Box plot of plasma microRNA-15a quantity in the three diagnostic groups.
Overall p = 0.001. T2DM vs. NGT p < 0.0001. IGT vs. NGT p = 0.01. Boxes are bordered at the 25th and the 75th percentile of the predictor variable and a median
line at the 50th percentile. Whiskers extend from the box to the upper and lower adjacent values and are capped with an adjacent line. Points below and above the
whiskers (10–90th percentile) are drawn as individual dots. (B) Diagnostic accuracy of microRNA-15a. ROCcurves for plasma (tot) microRNA-15a quantity (Qt) and
HbA1c (mmol) in predicting T2DM and IGT. AUC and p-values for comparison between curves are reported.
of small EV-microRNA quantity positively correlate with GCC
in NGT (p = 0.0001, rho = 0.95), but shows significant inverse
correlation in IGT (p= 0.0002, rho=−0.82).
DISCUSSION
Here, we showed that circulating total plasma and EV-
microRNA-15a increases in subjects with T2DM and associates
with clinical parameters of altered glucose metabolism.
Differences with a previous report that showed decreased
circulating microRNA-15a in diabetes may be due at least in
part to the different internal reference used (10). Importantly, in
our study in IGT, small EV-microRNA-15a quantity associates
with neuronal damage in the retina (decreased thickness of the
GCC), an alteration associated with early stage of retinopathy
and could represent useful biomarkers at the early phase of
the diabetic retinopathy. Interestingly, this association was not
observed when using whole circulating levels of microRNA-
15a, supporting the notion that small EV-contained miRNAs
provide different information when compared to plasmatic
microRNAs (11). Data showed for the first time that GCC
is decreased already in subjects with IGT and patients with
previously undiagnosed T2DM. This is in line with the emerging
neuropathic theory of diabetic retinopathy that hypothesizes an
earlier neuronal damage anticipating the development of the
glucose-mediated vascular injury eventually leading to retinal
dysfunction and vision loss (12). Although the organ/cellular
source of circulating microRNAs is difficult to decipher, initial
evidence suggests microRNA-15a is produced within pancreatic
beta cells, with its transcription being increased in overt T2DM
(13). As recently shown, EV-associated microRNA-15a could
be delivered to the retina triggering reactive oxygen species
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FIGURE 3 | T2DM associates with changes in extracellular vesicles (EVs) size distribution and microRNA-15a content. (A) EVs have been studied in a subgroup of
subjects: NGT, N = 9; IGT, N = 10; T2DM, N = 10. * Reported geometric means were adjusted for age and sex. Plots showing for each diagnostic group (NGT, IGT,
and T2DM) the distribution of mean vesicle concentrations for each size; vertical bar charts represent FDR and P-value for each size comparison; the red line indicates
P = 0.05; the red dot line indicates FDR = 0.10. (B,C) Box plot of EV- and small EV–microRNA-15a quantity in the three diagnostic groups. EV: NGT, N = 20; IGT, N
= 17; T2DM, N = 18. Small EV microRNA was obtained by normalizing the quantity of miRNA by the small EV concentration: NGT, N = 9; IGT, N = 10; T2DM, N =
10. Boxes are bordered at the 25th and the 75th percentile of the predictor variable and a median line at the 50th percentile. Whiskers extend from the box to the
upper and lower adjacent values and are capped with an adjacent line. Points below and above the whiskers (10–90th percentile) are drawn as individual dots.
production and activation of the pro-apoptotic pathways (9).
On the other side, another report showed that microRNA-15a
is downregulated within the diabetic retina, with subsequent
activation of pro-inflammatory and pro-angiogenic pathways
(14). Similarly, an in vitro study showed that high glucose
conditions decreased the expression of microRNA-15a in
cultured human retinal endothelial cells, promoting the pro-
inflammatory signaling of IL-1β, TNFα, and NF-κB (15).
These discrepancies highlight a potential tissue-dependent
regulation of microRNA-15a in the diabetic environment. On
the other side, they support a key role for this microRNA in
the pathogenesis of diabetic retinopathy, an observation that
might eventually reinforce its potential as a functional marker of
the disease.
MicroRNAs and their shuttles are currently being explored for
their ability to provide information about complex pathological
traits or multi-factorial diseases, such as T2DM complications
(16). Indeed, given their capacity to be finely modulated
by a wide variety of T2DM-relvant triggers, they represent
an ideal interface between environmental stimuli and the
genetic background, possibly providing additional information
compared to conventional risk factors (17). On the other
side, EVs isolation and miRNA dosages are not commonly
used in routine clinical practice, mainly to the long time
required for analysis and the lack of internationally accepted
method for standardization. These and other aspects must be
implemented before miRNAs can represent an additional tool for
diagnostic purposes.
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FIGURE 4 | Correlation between circulating microRNA-15a and retinal damage. Scatter plots for the correlation between (A) total plasma microRNA-15a quantity (Qt),
(B) EV-microRNA-15a quantity (Qt), (C) small EV-microRNA-15a quantity (Qt) and CGG thickness (µm) in the three diagnostic groups.
Circulating microparticles concentration reportedly
increases in subjects with diabetes and carry a specific
signature of microRNAs (18). We here demonstrated that
diabetic EVs are enriched in larger particles that could
reflect an increase in cellular damage in diabetes (19).
Interestingly, we detected a peak of small, exosome-like,
vesicles only in IGT donors potentially associated with
inflammation (20).
Our study limit resides in its observational nature and
relatively small sample sizewhich does not allow definitive
conclusion and proper adjustments for multiple risk factors.
On the other hand, it identifies a previously unknown
association between microRNA-15a and early retinal alterations
in preclinical diabetes. This observation can have a significant
relevance for the refinement of risk stratification and secondary
prevention of T2DM-associated complications.
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MATERIALS AND METHODS
Study Protocol
NGT, IGT and T2DM subjects were consecutively selected
based on plasma glucose (PG) levels after 2 h of a 75 gr
glucose load (OGTT) among those at intermediate/high risk
for T2DM, according to a risk score assessment questionnaire
(21) enrolled in a clinical observational study conducted at
IRCCS MultiMedica, Milan, Italy, for the prediction and early
diagnosis of diabetes mellitus (DIAPASON-DIAbetes Prediction
And Screening Observational study). The DIAPASON protocol
was approved by the institutional review boards of the IRCCS
MultiMedica [protocol number 24/2012(153)]. Participants
signed informed consent prior to laboratory screening. The
thickness of the GCC was measured by OCT apparatus (Cirrus
HD-OCT, Zeiss) analyzing an area of 6 × 6mm of six scanned
sectors around the fovea in both eyes. Exclusion criteria for the
OCT analysis were visual defects (refraction ≥ 4 diopters) or
concurrent glaucoma, keratoma, and macular degeneration.
RNA Extraction and microRNA
Expressional Analysis
For RNA extraction, 100 ul of plasma samples collected in
ethylene di-amine tetra-acetic acid (EDTA) anticoagulant tubes
were processed using miRNeasy Mini Kit (Qiagen, Hilden,
Germany). AfterTaqMan microRNA reverse transcription,
microRNa-15a expression was analyzed by the QuantStudio 6
Flex Real-Time PCR System (Applied Biosystems, Bradbury,
NJ, USA) in total plasma and isolated EVs and normalized
to the synthetic spike-in Cel-microRNA-39 (Qiagen, Hilden,
Germany). The quantity of assayed microRNAs and Cel-
microRNA-39 was retrieved relative to PCR data from a dilution
curve of a known quantity input.
EV Isolation and Quantification
One-hundred µL of plasma were used for the EV isolation
with a ready-made chromatography method known to eliminate
>95% of non-vesicular proteins (Exo-spin Blood, Cell Guidance
Systems, Cambridge, UK) (22). EVs purity and quantity were
measured by Nanoparticle Tracking Analysis, using Nanosight
NS300 (Malvern Panalytical Ltd) (23).
Statistical Methods
Categorical variables were compared using the χ2 test.
Normally and not-normally distributed continuous variables
were compared between diagnostic groups using the F-test or
the non-parametric Kruskal–Wallis test. The linear regression
model was used to evaluate the association between microRNA
expression levels and diagnostic group (NGT, IGT, or T2DM)
after adjustment by age and sex. The area under the receiver
operating characteristic curve (AUC) was used to determine the
discriminatory capability of microRNA-15a and HbA1c (mmol)
with respect to the diagnosis of T2DM or IGT. AUCs were
compared using the DeLong’s test. The correlation between
microRNA levels and clinical parameters was evaluated by the
Spearman correlation coefficient. For each EV size, we estimated
EV geometric mean concentrations in NGT, IGT and T2DM
groups, adjusting for age and sex with multiple linear regression
models. In addition, EV count for each size was naturally log-
transformed to approximate normality of residuals. Due to the
high number of comparisons, we used a multiple comparison
method based on Benjamini–Hochberg False Discovery Rate
(FDR) to calculate the FDR P-value. The association between
OCT parameters and diagnostic groups and the association
between microRNA levels and OCT parameters were evaluated
on eye-specific data. All reported p-values were two-sided. A p
< 0.05 was considered statistically significant. Statistical analyses
were performed with SAS 9.4 statistical software (SAS Institute
Inc., Cary, NC).
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